Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations
Expert Opinion on Drug Metabolism & Toxicology December 2, 2022 J. Carlier, S. Malaca, M. Huestis et al.
The psychedelic tryptamine 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) is metabolized by human hepatocytes into three phase I and four phase II metabolites, including N-oxidation and N-demethylation products as well as glucuronide and sulfate conjugates. These findings suggest that 4-OH-MPT-N-oxide and 4-hydroxy-N,N-propyltryptamine (4-OH-PT) can serve as biomarkers of intake after hydrolysis of glucuronide or sulfate conjugates in biological samples, while 4-OH-MPT-glucuronide is a useful biomarker when hydrolysis is not performed. The metabolic profile aligns with that of other tryptamine analogues, and further research is needed to confirm the specificity of these markers for forensic or clinical detection.